Education
About Us
Working with TipRanks
Follow Us
AngioDynamics (ANGO)
NASDAQ:ANGO
Earnings Data
Report Date
Apr 02, 2026Before Open (Confirmed)
Period Ending
2026 (Q3)Consensus EPS Forecast
-0.11Last Year’s EPS
-0.08Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call communicated strong operational momentum: broad-based revenue growth (8.8%), meaningful Med Tech strength (13%), standout product performance (Auryon +18.6%, AlphaVac +40.2%, NanoKnife +22.2%), margin expansion (gross margin +170 bps) and improved adjusted EBITDA and cash generation. Management raised full-year guidance and announced significant regulatory achievements that expand clinical opportunities. Headwinds include a Q2 decline in AngioVac, expected tariff costs ($4–$6M), temporary margin effects from manufacturing transitions, ongoing investments that will pressure H2 EBITDA, and remaining adjusted net loss. Overall, the positive operational and financial progress and upgraded guidance substantially outweigh the manageable near-term challenges.Company Guidance
Revenue Growth and Mix Shift
Total pro forma revenue grew 8.8% year-over-year to $79.4 million in Q2 FY2026. Med Tech grew 13% to $35.7 million and comprised 45% of total revenue (vs 43% a year ago), while Med Device increased 5.6% to $43.8 million, reflecting a favorable shift toward higher-growth, higher-margin Med Tech sales.
Auryon Sustained Momentum
Auryon revenue was $16.3 million, up 18.6% year-over-year and marking the 18th consecutive quarter of double-digit growth. Growth driven by increased hospital penetration, OBL and international adoption following CE Mark approval.
NanoKnife Strong Performance and CPT Code Tailwind
NanoKnife revenue rose 22.2% year-over-year to $7.3 million with probe sales up 14.4%. Q2 was a record quarter for prostate procedures. A new CPT code effective Jan 1 is expected to be a multi-quarter tailwind for adoption; international capital contributed approx. $1.0 million from a France distribution transaction.
Mechanical Thrombectomy: AlphaVac Acceleration and Regulatory Wins
Combined mechanical thrombectomy revenue increased 3.9% to $11.0 million. AlphaVac grew 40.2% year-over-year to $3.5 million and delivered sequential growth. The company received three regulatory milestones: IDE approval for the APEX-Return study (AlphaReturn blood management with AlphaVac for PE), IDE approval for the PAVE study (AngioVac for right-sided infective endocarditis), and 510(k) clearance for a modified AlphaVac F18 85 system expanding indications.
Margin Expansion and Manufacturing Progress
GAAP gross margin improved to 56.4% in Q2, a 170 basis point increase year-over-year, driven by product mix shift toward Med Tech, manufacturing transfer benefits and favorable channel transaction in France. Company accelerated manufacturing cost savings ahead of plan.
Profitability and Cash Generation Improvement
Adjusted EBITDA nearly doubled to $5.9 million (from $3.1 million prior year). Adjusted net loss narrowed to $0.1 million (adjusted loss per share $0.10) versus an adjusted net loss of $1.7 million a year ago. Cash and cash equivalents rose to $41.6 million (from $38.8 million), and the company generated $4.7 million of cash in the quarter and expects to be cash flow positive for FY2026.
Raised Full-Year Guidance
Management raised FY2026 revenue guidance to $312–$314 million (up from $308–$313 million), implying 6.6%–7.3% growth over FY2025. Med Tech sales are now expected to grow 14%–16%; Med Device 0%–1% (up from flat). Adjusted EBITDA guidance was raised to $8–$10 million (from $6–$10 million).
Favorable Legal Outcome
U.S. Court of Appeals affirmed a prior judgment invalidating C.R. Bard's patents, closing long‑running litigation and removing the potential $3 million payment under the settlement agreement.
ANGO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ANGO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Jan 06, 2026 | $13.23 | $11.44 | -13.53% |
Oct 02, 2025 | $11.07 | $11.74 | +6.05% |
Jul 15, 2025 | $9.63 | $8.65 | -10.18% |
Apr 02, 2025 | $9.66 | $10.86 | +12.42% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does AngioDynamics (ANGO) report earnings?
AngioDynamics (ANGO) is schdueled to report earning on Apr 02, 2026, Before Open (Confirmed).
What is AngioDynamics (ANGO) earnings time?
AngioDynamics (ANGO) earnings time is at Apr 02, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ANGO EPS forecast?
ANGO EPS forecast for the fiscal quarter 2026 (Q3) is -0.11.
